Skip to main content
COVID-19

Antidepressant Medication Management (AMM)

What is the AMM — HEDIS® Measure?

Based on current NCQA HEDIS recommendations for best practices, members 18 years of age and older who were treated with antidepressant medication and had diagnosis of major depression should remain on antidepressant medication treatment.

The following will meet numerator (eligible population) compliance:

  • Two rates are reported:
    • Effective Acute Phase Treatment: Members who remained on an antidepressant medication for at least 84 days (12 weeks).
    • Effective Continuation Phase Treatment: The percentage of members who remained on an antidepressant medication for at least 180 days (six months).

Best Practices

  • Discuss with patients the importance of taking medication as prescribed and to remain on medication for a minimum of six months, even when the patient starts to feel better.
  • Discuss with patients the risks of stopping medication before six months. Recommend a consultation before stopping.
  • Educate patients on possible side effects and length of time for the medication to have the desired effect.
  • Schedule a follow-up appointment before the patient leaves the office and send appointment reminders.
  • Develop a tracking method for patients prescribed antidepressants and require staff to follow up with patients that miss or cancel their appointment.
  • When available, use gap lists to help manage your total population.
  • Consider the patient’s work schedule as a barrier to the visit, and offer extended evening or weekend hours, and telemedicine.

NCQA HEDIS Population Definition for This Measure

Population: Members 18 years and older as of April 30 of the measurement year who were treated with an antidepressant medication, had diagnosis of major depression and remained on an antidepressant medication treatment

Line of Business: Commercial, Medicaid, Medicare

Antidepressant Medications:

Amitriptyline
Amitriptyline-chlordiazepoxide
Amitriptyline-perphenazine
Amoxapine
Bupropion
Citalopram
Clomipramine
Desipramine
Desvenlafaxine
Doxepin (>6 mg)
Duloxetine
Escitalopram
Fluoxetine
Fluoxetine-olanzapine
Fluvoxamine
Imipramine
Isocarboxazid
Levomilnacipran
Maprotiline
Mirtazapine
Nefazodone
Nortriptyline
Paroxetine
Phenelzine
Protriptyline
Selegiline
Sertraline
Tranycypromine
Trazodone
Trimipramine
Venlafaxine
Vilazodone
Vortioxetine

To learn more about your practice’s current HEDIS performance, 2022 HEDIS Value sets for this or other measures, or for assistance in compliance with the HEDIS guidelines, please email BH_HEDISTeam@HorizonBlue.com or visit https://www.horizonblue.com/providers/resources/guidelines/hedis-measurement-year-my-2022-provider-tips-optimizing-hedis-results

Reference: Antidepressant Medication Management (AMM), NCQA HEDIS 2022 Tech Specifications